Please login to the form below

Not currently logged in
Email:
Password:

UK launch of RebiDose for treatment of MS

Merck Serono has launched the UK's first pre-filled, single-use disposable pen for the self-administration of Rebif

Merck's division for innovative prescription pharmaceuticals, Merck Serono, has launched the UK's first pre-filled, single-use disposable pen for the self-administration of Rebif, a disease-modifying drug for the treatment of relapsing forms of multiple sclerosis (MS).

The RebiDose device is a pre-filled, pre-loaded, single-use disposable pen and is the first and only injection delivery device that needs no assembly or priming by the patient.

According to MS nurse specialist at Herefordshire PCT, Del Thomas: "The simplicity of the RebiDose pen may be ideal for those patients with MS who have significant cognitive, visual or dexterity impairment. The needle is hidden and the rubber grips can maximise control by the patient throughout the entire injection process."

RebiDose pens are available in strengths of 22mcg and 44mcg as well as the titration pack for initiation of treatment. Each pen can be stored in the fridge for up to 18 months, and at room temperature of up to 25 degrees for a single period of 14 days, giving patients flexibility with storage conditions when travelling. 

RebiDose has been approved in the EU. While the UK was the first to launch RebiDose, other European countries are expected to follow shortly.

3rd November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics